Björn Velin
Björn Velin Chief Executive Officer
CEO since 2019. Employed at the company since 2019

Education
Executive MBA from Lund University, Sweden

Experience and prior assignments
More than 30 years of experience from the pharmaceutical industry, whereof the last 25 at Lundbeck A/S, where he has held several international leading roles and executive positions: Sales and Marketing Director for Sweden, Managing Director for The Netherlands and Managing Director Sweden. Prior to joining Dizlin Pharmaceuticals, he spent four years abroad as President for Lundbeck, Japan.

Leif Bring
Leif BringExecutive Director
Executive Director since 2019. Employed at the company since 2019

Education
MSc from Chalmers Technical University, Gothenburg, and studies in Economy & Finance at Mälardalen University, Sweden

Other assignments
CEO of the Intercedo Group and Chairman of Dizlin Pharmaceuticals AB

Experience and prior assignments
More than 35 years of experience in corporate development and executive management and has been a board member of Transientic Interactions AB and Chairman of the Board of Robust Ståldörrar. Leif Bring has a broad experience from international business and was based in Atlanta, when he held the position of Director Business Development at ABB Flakt Inc. He has worked several years with corporate development in a joint project with the ABB Group and Boston Consulting Group. Previously, he has also been Regional Manager, Middle East for the ABB Group as well as CEO of Dizlin Pharmaceuticals AB, 2005-2019. He is one of the founders of Dizlin Pharmaceuticals AB.

Elias Eriksson
Elias Eriksson Chief Medical Officer
Chief Medical Officer, contracted since 2013

Education
Medical Doctor and Professor of Pharmacology at the Department of Physiology and Neuroscience, Sahlgrenska Academy, University of Gothenburg, Sweden

Other assignments
Board member at Dizlin Pharmaceuticals AB since 2018

Experience and prior assignments
Active in preclinical and clinical neuropsychopharmacological research for four decades, written approximately 300 scientific papers within these fields, and supervised 20 PhD students. Has been a member of the Scientific Council for Medicine and Health at the Swedish Research Council and is currently a Board member and the Secretary of the International College of Neuropsychopharmacology (CINP).

Mats Ehrnebo
Mats Ehrnebo Product Development Director
Contracted as consultant since 2014

Education
PhD, M Pharm Sci, Associate Professor, Faculty of Pharmacy, University of Uppsala, Sweden

Other assignments
Senior Adviser in Drug Development and Chairman of the Board at Pharm Assist Sweden AB

Experience and prior assignments
More than 40 years of experience from the life science, pharmaceutical and medical device industries. During several years, he been a board member and secretary of the Swedish Society for Clinical Studies. Since 1980, he has been working as a consultant in his own Contract Research Organisation (CRO), and later on as Head of Nordic Regulatory Affairs and Clinical Trials for an international CRO. In 1996, he started Pharm Assist Sweden AB. In 2014, he joined the Infudopa project at Dizlin Pharmaceuticals AB. He is together with Elias Eriksson, Nil Dizdar and Leif Bring inventor of the infusion solution Infudopa™.

Richard Gradin
Richard GradinChief Commercial Officer
Contracted since July 2021

Education
Dr of Naprapathy, University of Chicago (Swe. leg. Naprapat)
Courses in Marketing Management

Experience and prior assignments
More than 25 years of experience from sales, marketing, and management positions in both pharmaceutical and medical device industry. As a leader his strength and focus are on development, growth, and progress. He has worked in small and large organizations in Sweden as well as internationally. His previous international experience has been in the areas of product launches and market expansions.

Marie Gårdmark
Marie Gårdmark Regulatory Affairs Director
Contracted 2020

Education
MSc Pharm, PhD

Other assignments
CEO of RegSmart Life Science AB

Experience and prior assignments
More than 20 years of experience from regulatory in drug development. As Director at the Swedish MPA, she was responsible for drug approvals including scientific advice and clinical trials. As regulator, she has actively contributed to development of new guidelines and legislation. She has worked in big- and small pharma developing global regulatory strategies for several compounds from early development up to market approval. She has led due diligence activities and scientific advice meetings in EU and the US.

Daniel Mackey
Daniel MackeyChief Financial Officer
CFO and employed since November 2021

Education
BS, Economics, State University of New York College at Plattsburgh, US

Experience and prior assignments
More than 20 years of finance and controlling experience in the finance and life science sector. He has held senior management positions at Nordea in Stockholm, Investors Trust Ireland in Dublin, and most recently the CFO position at Infant Bacterial Therapeutics AB.